Health Canada’s approval of Eloxatin was based on clinical data collected over several years. The MOSAIC trial compared the efficacy and evaluated the safety of Eloxatin in combination with an infusional schedule of 5-FU/LV (FOLFOX4) to infusional 5-FU/LV alone, in patients with stage II or III colon cancer who had undergone complete resection of the primary tumour. In the overall study population, disease-free survival statistically and significantly improved in the Eloxatin combination arm compared to infusional 5-FU/LV alone. Survival data at six years show a numerical improvement in overall survival in patients with stage III colon cancer.
Eloxatin is a platinum agent which binds to the DNA in cancer cells and inhibits the replication process, causing the eventual death of the cancer cell.